Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Elevated Serum B12 levels were found at diagnosis in five of eleven patients with primary hepatocellular carcinoma. During chemotherapy either with CB3717 or VP16 the serum B12 rose dramatically, in one case reaching levels ten times the upper limit of normal. However, the serum LD activities did not change in parallel with the serum B12 levels suggesting that there was little necrosis of the tumour or the liver. With two out of five patients with other types of cancer the serum B12 levels also increased but less markedly. This data seems to suggest that the serum B12 level may not be as good a tumour marker for hepatocellular carcinoma as has been suggested and indeed may be influenced by the chemotherapeutic agent.

Type

Journal article

Journal

J Surg Oncol

Publication Date

02/1987

Volume

34

Pages

100 - 103

Keywords

Adult, Aged, Carcinoma, Hepatocellular, Female, Folic Acid, Follow-Up Studies, Humans, L-Lactate Dehydrogenase, Liver Cirrhosis, Liver Neoplasms, Male, Middle Aged, Quinazolines, Vitamin B 12, alpha-Fetoproteins